Woolf, Tod M.
Gurumurthy, Channabasavaiah B.
Boyce, Frederick
Kmiec, Eric B.
Article History
First Online: 17 March 2017
Competing interests
: T.M.W., F.B. and E.B.K. own shares in ETAGEN Pharma, where T.M.W. served as chief executive officer, and F.B. and E.B.K. serve as scientific advisors. T.M.W. began a position as a technology licensing officer at the Massachusetts Institute of Technology (MIT) Technology Licensing Office on 9 November 2016, after the submission of this article, but before the final post-submission editing was completed. T.M.W. does not work on licensing of CRISPR–Cas9 at MIT and does not have any financial interest in CRISPR–Cas9 at MIT.